These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 8109915)

  • 21. A new tricyclic fluoroquinolone, rufloxacin (MF-934), with interesting antibacterial and pharmacokinetic characteristics.
    Segre G; Cerretani D; Cerri D; Moltoni L
    Drugs Exp Clin Res; 1988; 14(12):747-54. PubMed ID: 3253051
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic disposition of the new fluoroquinolone antibacterial agent DW116 in rats.
    Park YH; Jung BH; Chung BC; Park J; Mitoma C
    Drug Metab Dispos; 1997 Sep; 25(9):1101-3. PubMed ID: 9311628
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Penetration of rufloxacin into human prostatic tissue and fluid.
    Boerema JB; Bach D; Jol C; Pahlmann W
    J Antimicrob Chemother; 1991 Oct; 28(4):547-54. PubMed ID: 1662190
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Absence of effect of rufloxacin on theophylline pharmacokinetics in steady state.
    Kinzig-Schippers M; Fuhr U; Cesana M; Müller C; Staib AH; Rietbrock S; Sörgel F
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2359-64. PubMed ID: 9736563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of 1-(5-fluoro-2-pyridyl)-6-fluoro-7-(4-methyl-1- piperazinyl)-1,4-dihydro-4-oxoquinolone-3-carboxylic acid hydrochloride (DW-116), a new quinolone antibiotic in rats.
    Yu IL; Chung SJ; Lee MH; Shim CK
    J Pharm Sci; 1997 May; 86(5):550-3. PubMed ID: 9145377
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Excretion of new quinolones and their glucuronide conjugates into human bile.
    Murakami K; Tanimura H; Ishimoto K; Uchiyama K; Yukawa H; Onishi H; Iwakura K
    Drugs; 1995; 49 Suppl 2():331-2. PubMed ID: 8549351
    [No Abstract]   [Full Text] [Related]  

  • 27. The penetration of rufloxacin into sites of potential infection in the respiratory tract.
    Wise R; Andrews J; Imbimbo BP; Greaves I; Honeybourne D
    J Antimicrob Chemother; 1993 Dec; 32(6):861-6. PubMed ID: 8144426
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biliary excretion of cefixime: assessment in patients provided with T-tube drainage.
    Westphal JF; Jehl F; Schloegel M; Monteil H; Brogard JM
    Antimicrob Agents Chemother; 1993 Jul; 37(7):1488-91. PubMed ID: 8363380
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biliary elimination and hepatic disposition of a new fluoroquinolone, temafloxacin: experimental evaluation.
    Brogard JM; Koechlin C; Westphal JF; Blicklé JF; Dorner M; Jehl F
    Drugs Exp Clin Res; 1990; 16(8):407-16. PubMed ID: 2097145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Decreased biliary excretion of piperacillin after percutaneous relief of extrahepatic obstructive jaundice.
    Blenkharn JI; Habib N; Mok D; John L; McPherson GA; Gibson RN; Blumgart LH; Benjamin IS
    Antimicrob Agents Chemother; 1985 Dec; 28(6):778-80. PubMed ID: 4083861
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simultaneous determination of rufloxacin and theophylline by high-performance liquid chromatography in human plasma.
    Carlucci G; Mazzeo P; Palumbo G
    Analyst; 1995 Oct; 120(10):2493-5. PubMed ID: 8540619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans.
    Nakashima M; Uematsu T; Kosuge K; Kusajima H; Ooie T; Masuda Y; Ishida R; Uchida H
    Antimicrob Agents Chemother; 1995 Dec; 39(12):2635-40. PubMed ID: 8592993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single-dose rufloxacin versus 3-day norfloxacin treatment of uncomplicated cystitis: clinical evaluation and pharmacodynamic considerations.
    Del Río G; Dalet F; Aguilar L; Caffaratti J; Dal-Ré R
    Antimicrob Agents Chemother; 1996 Feb; 40(2):408-12. PubMed ID: 8834888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analytical procedure for the determination of rufloxacin, a new pyridobenzothiazine, in human serum and urine by high-performance liquid chromatography.
    Carlucci G; Palumbo G
    J Chromatogr; 1991 Mar; 564(1):346-51. PubMed ID: 1860932
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of prulifloxacin. 1st communication: absorption, distribution and excretion in rats, dogs and monkeys after a single administration.
    Okuyama Y; Momota K; Morino A
    Arzneimittelforschung; 1997 Mar; 47(3):276-84. PubMed ID: 9105546
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activity of a new quinolone, rufloxacin, against nosocomial isolates.
    Mattina R; Cocuzza CE; Cesana M; Bonfiglio G
    Chemotherapy; 1991; 37(4):260-9. PubMed ID: 1665122
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatobiliary transport kinetics of HSR-903, a new quinolone antibacterial agent.
    Murata M; Tamai I; Sai Y; Nagata O; Kato H; Sugiyama Y; Tsuji A
    Drug Metab Dispos; 1998 Nov; 26(11):1113-9. PubMed ID: 9806954
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Double-blind, comparative study of rufloxacin once daily versus amoxicillin three times a day in treatment of outpatients with exacerbations of chronic bronchitis.
    Klietmann W; Cesana M; Rondel RK; Focht J
    Antimicrob Agents Chemother; 1993 Nov; 37(11):2298-306. PubMed ID: 8285609
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The biliary excretion and pharmacokinetics of mezlocillin in jaundiced patients with external bile drainage.
    Dooley JS; Gooding A; Hamilton-Miller JM; Brumfitt W; Sherlock S
    Liver; 1983 Aug; 3(4):201-6. PubMed ID: 6672502
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacodynamic effects of subinhibitory concentrations of rufloxacin on bacterial virulence factors.
    Braga PC; Sala MT; Dal Sasso M
    Antimicrob Agents Chemother; 1999 May; 43(5):1013-9. PubMed ID: 10223908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.